EpiBiologics

EpiBiologics is advancing bispecific antibodies that selectively degrade membrane and soluble proteins, including GPCRs. Our EpiTAC platform leverages a novel atlas of tissue-selective degrader receptors to drive deep and durable efficacy. The company was founded in 2022 based on pioneering work from Dr. Jim Wells at UCSF. Headquartered in the SF Bay Area, EpiBiologics is backed by leading healthcare investors and building a clinical stage pipeline for oncology and immunology. For more information, please visit epibiologics.com and follow us on LinkedIn.